The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 28, 2017
Filed:
May. 22, 2013
Applicants:
Wuhan Therasource Biosciences Inc, Wuhan, Hubei, CN;
Shanghai Junshi Bioscience Co., Ltd, Shanghai, CN;
Inventors:
Assignees:
WUHAN THERASOURCE BIOSCIENCES INC., Wuhan, Hubei Province, CN;
SHANGHAI JUNSHI BIOSCIENCE CO., LTD., Shanghai, CN;
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); C07K 16/24 (2006.01); A61K 39/395 (2006.01); C12P 21/08 (2006.01); C12N 15/63 (2006.01); C12N 15/09 (2006.01); C12N 5/10 (2006.01); C12N 5/12 (2006.01); C07K 16/28 (2006.01); C07K 14/525 (2006.01); C12P 21/02 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/241 (2013.01); A61K 39/3955 (2013.01); C07K 16/2875 (2013.01); C12N 15/09 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C12N 5/10 (2013.01); C12N 5/12 (2013.01); C12P 21/02 (2013.01);
Abstract
The present invention belongs to the field of biopharmaceutics. Disclosed is an anti-BLyS antibody. The anti-BLyS antibody specifically targets BLyS, can combine with a B lymphocyte stimulating factor, and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3-Fc thereof. Also provided are uses of the anti-BLyS antibody in the manufacture of a medicament for preventing and/or treating diseases caused by the excessive proliferation of B cells such as systemic lupus erythematorsus.